OPUS GENETICS INC (IRD)
Health Care · Gene therapy for ophthalmic and retinal diseases · NASDAQ
Clinical-stage biopharmaceutical company developing AAV-based gene therapies to restore vision in patients with inherited retinal diseases.
What OPUS GENETICS INC does
Opus Genetics is a clinical-stage biopharmaceutical company focused on developing gene therapies to treat inherited retinal diseases (IRDs) and other ophthalmic disorders. The company's pipeline includes seven adeno-associated virus (AAV)-based gene therapy programs targeting genetic causes of retinal degeneration, with lead candidates OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, complemented by a FDA-approved small-molecule therapy, Phentolamine Ophthalmic Solution 0.75%. Treatments are administered via subretinal injection to directly target the site of disease and are designed as durable, one-time interventions addressing rare genetic conditions affecting over 350,000 people in the U.S.
Themes: ["Gene therapy / inherited retinal diseases","Rare ophthalmic disorders","AAV-based therapeutics","Vision restoration","Orphan drug development"]
Fundamentals
- Price$4.02 as of 2026-07-09 close
- Market cap$332M as of 2026-07-10
- 1-year return+262.2% as of 2026-07-09 close
- Net margin-892.4% as of 2026-07-10
- Gross margin+87.5% as of 2026-07-10
- ROE-316.4% as of 2026-07-10
- Debt / equity0.07 as of 2026-07-10
- Revenue growth (YoY)-12.2% as of 2026-07-10
- Revenue CAGR (3y)-29.1% SEC XBRL
- Beta0.58 as of 2026-07-10
Key risks (from latest filing)
["Clinical-stage company with no approved gene therapies and negative cash flow; company is unprofitable with net margin of -892% and dependent on funding from Series B preferred stock issuance and at-the-market offerings to continue operations.","Significant warrant liability exposure; fair value changes in warrant liabilities caused a $51.4 million loss in Q1 2026, representing material financial volatility unrelated to operational performance.","Gene therapy development carries substantial regulatory, safety, and technical execution risks; success depends on clinical trial outcomes for multiple rare disease indications with limited patient populations."]
Competitors & peers
- 4D Molecular Therapeutics
- Editas Medicine
- Iviva Biosciences
- Nightstar Therapeutics
- Spark Therapeutics
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.